Evolus Statistics
Total Valuation
Evolus has a market cap or net worth of $598.42 million. The enterprise value is $718.05 million.
| Market Cap | 598.42M |
| Enterprise Value | 718.05M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolus has 66.05 million shares outstanding. The number of shares has increased by 2.34% in one year.
| Current Share Class | 66.05M |
| Shares Outstanding | 66.05M |
| Shares Change (YoY) | +2.34% |
| Shares Change (QoQ) | +1.14% |
| Owned by Insiders (%) | 11.05% |
| Owned by Institutions (%) | 64.96% |
| Float | 51.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 209.24 |
| PS Ratio | 1.88 |
| Forward PS | 1.64 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.70
| Current Ratio | 1.70 |
| Quick Ratio | 1.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.34 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -5.68% |
| Return on Invested Capital (ROIC) | -10.02% |
| Return on Capital Employed (ROCE) | -14.51% |
| Weighted Average Cost of Capital (WACC) | 10.86% |
| Revenue Per Employee | $896,567 |
| Profits Per Employee | -$97,261 |
| Employee Count | 353 |
| Asset Turnover | 1.33 |
| Inventory Turnover | 3.16 |
Taxes
In the past 12 months, Evolus has paid $654,000 in taxes.
| Income Tax | 654,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.87% in the last 52 weeks. The beta is 1.36, so Evolus's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | +18.87% |
| 50-Day Moving Average | 7.18 |
| 200-Day Moving Average | 6.04 |
| Relative Strength Index (RSI) | 70.79 |
| Average Volume (20 Days) | 1,195,406 |
Short Selling Information
The latest short interest is 5.85 million, so 8.86% of the outstanding shares have been sold short.
| Short Interest | 5.85M |
| Short Previous Month | 5.57M |
| Short % of Shares Out | 8.86% |
| Short % of Float | 11.47% |
| Short Ratio (days to cover) | 6.12 |
Income Statement
In the last 12 months, Evolus had revenue of $316.49 million and -$34.33 million in losses. Loss per share was -$0.53.
| Revenue | 316.49M |
| Gross Profit | 210.16M |
| Operating Income | -21.66M |
| Pretax Income | -33.68M |
| Net Income | -34.33M |
| EBITDA | -12.77M |
| EBIT | -21.66M |
| Loss Per Share | -$0.53 |
Balance Sheet
The company has $45.17 million in cash and $164.80 million in debt, with a net cash position of -$119.63 million or -$1.81 per share.
| Cash & Cash Equivalents | 45.17M |
| Total Debt | 164.80M |
| Net Cash | -119.63M |
| Net Cash Per Share | -$1.81 |
| Equity (Book Value) | -30.90M |
| Book Value Per Share | -0.47 |
| Working Capital | 68.81M |
Cash Flow
In the last 12 months, operating cash flow was -$15.38 million and capital expenditures -$2.90 million, giving a free cash flow of -$18.28 million.
| Operating Cash Flow | -15.38M |
| Capital Expenditures | -2.90M |
| Depreciation & Amortization | 8.89M |
| Net Borrowing | 9.98M |
| Free Cash Flow | -18.28M |
| FCF Per Share | -$0.28 |
Margins
Gross margin is 66.40%, with operating and profit margins of -6.84% and -10.85%.
| Gross Margin | 66.40% |
| Operating Margin | -6.84% |
| Pretax Margin | -10.64% |
| Profit Margin | -10.85% |
| EBITDA Margin | -4.04% |
| EBIT Margin | -6.84% |
| FCF Margin | n/a |
Dividends & Yields
Evolus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.34% |
| Shareholder Yield | -2.34% |
| Earnings Yield | -5.78% |
| FCF Yield | -3.08% |
Analyst Forecast
The average price target for Evolus is $15.00, which is 65.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.00 |
| Price Target Difference | 65.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 15.82% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolus has an Altman Z-Score of -1.63 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.63 |
| Piotroski F-Score | 2 |